Intrinsic cancer cells and the tumor-infiltrating immune cells (TIICs) recruited to the immune microenvironment define the malignant phenotype of lung squamous cell carcinoma (LUSC). Understanding more about the immune microenvironment of LUSC enables the selection of high-risk patients who would derive benefit from immunotherapy. Based on large public LUSC cohorts obtained from TCGA and GEO datasets, 22 types of infiltrating immune cell subgroups were evaluated by CIBERSORT. Meta-analysis, principal component analysis (PCA), single-sample gene set enrichment analysis (ssGSEA), and hierarchical clustering analysis were used to evaluate specific immune responses of LUSC. The distribution of TIICs of LUSC was entirely different from normal. T...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
Lung cancer is the cancer responsible for the most deaths worldwide. Treatment is multimodal and bas...
Immune cells of the tumor microenvironment are central but erratic targets for immunotherapy. The ai...
Lung tissue is abundant with immune cells that form a powerful first defense against exotic particle...
Summary: The immunogenomic features of tumor-adjacent lungs (TALs) in stage I lung squamous cell car...
Aims: Development of effective immune-based therapies for patients with non-small-cell lung carcinom...
Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) ...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
Recent studies indicate that the abnormal microenvironment of tumors may play a critical role in car...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
BackgroundCancer stem cells (CSCs) refer to cells with self-renewal capability in tumors. CSCs play ...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
Lung cancer is the cancer responsible for the most deaths worldwide. Treatment is multimodal and bas...
Immune cells of the tumor microenvironment are central but erratic targets for immunotherapy. The ai...
Lung tissue is abundant with immune cells that form a powerful first defense against exotic particle...
Summary: The immunogenomic features of tumor-adjacent lungs (TALs) in stage I lung squamous cell car...
Aims: Development of effective immune-based therapies for patients with non-small-cell lung carcinom...
Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) ...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
There is still no ideal predictive biomarker for immunotherapy response among patients with non-smal...
Recent studies indicate that the abnormal microenvironment of tumors may play a critical role in car...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
BackgroundCancer stem cells (CSCs) refer to cells with self-renewal capability in tumors. CSCs play ...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
Lung cancer is the cancer responsible for the most deaths worldwide. Treatment is multimodal and bas...
Immune cells of the tumor microenvironment are central but erratic targets for immunotherapy. The ai...